ID: MRFR/Pharma/2743-HCR | February 2021 | Region: Global | 90 pages
The treatment for serotonin syndrome consists of discontinuing medications contributing to the condition. For serious cases, other treatments for managing associated symptoms may be used. For serious cases with a threat to life gastrointestinal decontamination using activated charcoal is performed. Sedatives such as benzodiazepines are used for agitated patients. High fever is a common symptom of serotonin syndrome which reaches extremely high temperatures greater than forty centigrade. To control hyperthermia cooling measures may be needed. Serotonin antagonist such as cyproheptadine may be needed.
The serotonin syndrome market restraints are the low number of cases and equally low number of fatalities associated with the syndrome with less than 1% cases consuming serotonin syndrome causing drugs developing the diseases. Mild symptoms occur in about 15% of SSRI overdoses.
Considering all these factors, the serotonin syndrome market is expected to reach USD 400 million by the end of 2023, serotonin syndrome market is projected to growing at a CAGR of ~ 2.3 % during 2017-2023.
Sources: Mayo Clinic, MRFR Analysis.
Figure 1 Serotonin syndrome market by Surgery, 2016 (% Market Share)
The serotonin syndrome market is segmented on the basis of drug treatment, and end users. Based on drug treatment, the market has been segmented as serotonin antagonists, supportive care (Muscle relaxants, the control of autonomic instability, anti-hyperthermics, antihypertensive and others. Based on the end users, the market has been segmented as hospitals, point of care and others.
US accounts for the maximum market share due to greater use of medications and greater expenditure on healthcare. The faster market uptake of new technology and devices in the US is also an important driver of the market for global serotonin syndrome diagnosis and treatment. Europe is the second largest market due to large disposable income and rising awareness. Asia Pacific region is expected to have the most future potential and it is estimated to be led by China and India. The Middle East & Africa market is led by the gulf nations particularly Saudi Arabia and UAE. The regions of Africa are expected to witness a moderate growth due to poor economic and political conditions and poor healthcare penetration.
Key players of Serotonin syndrome market:
Key players profiled in the report are AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A., Ciron Drugs & Pharmaceuticals Pvt. Ltd. and others. The report for Serotonin syndrome market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug Treatment, and End Users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AstraZeneca Plc., Eli Lilly and Company, Forest Laboratories Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc. and Sanofi S.A., Ciron Drugs & Pharmaceuticals Pvt. Ltd. and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Serotonin syndrome market is expected to exhibit a CAGR of 2.3% from 2017 to 2023.
Serotonin syndrome market size can reach USD 400 million by 2023.
North America can dominate the global serotonin syndrome market till 2023.
Asia Pacific (APAC) has the highest potential for growth in the global serotonin syndrome market.
AstraZeneca Plc., Johnson & Johnson, Merck & Co., Inc., Forest Laboratories Inc., Pfizer, Inc., Sanofi S., Eli Lilly and Company, Ciron Drugs & Pharmaceuticals Pvt. Ltd., and GlaxoSmithKline plc are notable players of the global serotonin syndrome market.
1.2 scope of study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.3 Market Structure:
2. Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3. Market dynamics
3.4 Macroeconomic Indicators
4. Market factor analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
4.4 Threat Of New Entrants
4.5 Threat Of Substitutes
4.6 Intensity Of Rivalry
5. Global Serotonin Syndrome Market, by Drug Treatment
5.1 Serotonin Antagonists
5.2 Supportive Care
5.2.1 Muscle Relaxants
5.3 Gastrointestinal Decontamination
6. Global Serotonin Syndrome Market, By End Users
6.2 Point Of Care
7. Global Serotonin Syndrome Market, By Region
7.1 North America
7.4 Middle East & Africa
8. Competitive landscape
8.1 Major Strategies Adopted By Market Players
8.1.1 Strategic Partnership
8.1.2 Merger & Acquisition
9. Company profile
9.1 AstraZeneca Plc.
9.1.2 Product Overview
9.1.4 Key Developments
9.2 Eli Lilly and Company
9.2.2 Product Overview
9.2.4 Key Developments
9.3 Forest Laboratories Inc.
9.3.2 Product Overview
9.3.4 Key Development
9.4 GlaxoSmithKline plc.
9.4.2 Product Overview
9.4.4 Key Developments
9.5 Johnson & Johnson
9.5.2 Product Overview
9.5.4 Key Developments
9.6 Pfizer, Inc.
9.6.2 Product Overview
9.6.4 Key Developments
9.7 Sanofi S.A.
9.7.2 Product Overview
9.7.4 Key Developments
9.8 Ciron Drugs & Pharmaceuticals Pvt. Ltd.
9.8.2 Product Overview
9.8.4 Key Developments
9.9 Merck & Co., Inc.
9.9.2 Product Overview
9.9.4 Key Developments
10.1 Key Findings
10.1.1 From Ceo’s Viewpoint
10.1.2 Unmet Needs Of The Market
10.2 Key Companies To Watch
10.3 Prediction Of Serotonin Syndrome Treatment Industry